Industrial Biotechnology Corporation Engages ProteinOne for Vectoring, Strain Development and Bio-Repository Services Tuesday October 24, 10:25 am ET
SARASOTA, FL--(MARKET WIRE)--Oct 24, 2006 -- Industrial Biotechnology Corporation (Other OTC:IBTY.PK - News) (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, today announced the selection of ProteinOne to provide and enhance IBC's biological system design, vectoring, strain development and bio-repository services for targeted compounds. ADVERTISEMENT
Dr. Hui Ge, Vice President and Chief Scientific Officer for ProteinOne and former Head of Transcriptional Mechanisms at the National Institutes of Health stated, "We are happy to assist IBC in commercializing their platform of technologies, enabling them to design, develop and manufacture low-cost, high-volume biological chemicals for a range of industries. IBC has exciting proprietary technologies combined with a very experienced science and development team. Our protein expression and production core competency and expertise is a perfect match. ProteinOne is pleased to work in conjunction with IBC science staff, assisting the development of the many compounds currently in their pipeline."
"The services of ProteinOne will play a key role for some of our targeted compounds in the ALCHEMx Production Platforms(TM), which is our biological chemical production and commercialization assembly line. We possess a scientific management team and strategic partners that have vast and significant experience in the design, development, implementation and large scale manufacturing of biopharma compounds. These same development principals can now be applied to our technologies but without the high costs that are normally associated with the pharmaceutical industry and the development of a new drug or compound. Via our proprietary technologies and patents we are implementing new bio pathways for compounds that have large volumes and are in demand in a variety of industries that traditionally have been made only synthetically. This means manufacturing these targeted compounds at lower costs, using bio-renewable resources that have significantly less environmental impact than traditional methods. We are delighted to have ProteinOne as a partner," said Andy Badolato, CEO of IBC.
About ProteinOne
ProteinOne is a leading protein bioreagent company that develops, and globally markets innovative, highly purified, active recombinant proteins, protein assay kits and the Active Protein Array platform. ProteinOne's protein portfolio is used in scientific and medical advancement associated with disease management, new biopharmaceutical, assay and therapeutic development. The company's partnerships with medical research laboratories, government, and pharmaceutical institutions facilitate the evolution of molecular discovery founded in the human genome era by further understanding the functional gene protein relationship. The company sets this new standard with its team of protein chemists compiled from NIH, NCI, Karolinska Institute and Johns Hopkins under the leadership of Dr. Hui Ge, Vice President and Chief Scientific Officer. This team and their years of experience in cloning, various expression systems and in protein purification has been the key to ProteinOne's success. The track record of success has lead ProteinOne to major partnerships with key institutes such as the NIH, NCI and various pharmaceutical companies. For more information visit: www.ProteinOne.com
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) enables the biological production of chemicals through a combination of licensed patents, intellectual property and proprietary systems. We accomplish this through our ALCHEMx Productions Platforms(TM) which are a systematic, streamlined approach to biologically manufacturing chemicals more efficiently, at significantly lower costs, and with substantially lower environmental impact than traditional methods. IBC and its partners plan to produce and market new and established biologically produced chemicals to the pharmaceutical, bio-energy, agricultural, biopesticides, fine chemicals, flavors and fragrances, cosmaceuticals, biomaterials and biopolymer industries. For more information about Industrial Biotechnology Corporation, please visit its website at www.industrialbiotechnology.com.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Date Open High Low Last Change Volume % Change 10/27/06 1.2500 1.2800 1.1000 1.2300 +0.1300 171729 +11.82%
Composite Indicator Trend Spotter TM Buy
Short Term Indicators 7 Day Average Directional Indicator Buy 10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Buy 20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy 20-Day Average Volume - 39690
Medium Term Indicators 40 Day Commodity Channel Index Buy 50 Day Moving Average vs Price Buy 20 - 100 Day MACD Oscillator Sell 50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 50% - Buy 50-Day Average Volume - 21348
Long Term Indicators 60 Day Commodity Channel Index Buy 100 Day Moving Average vs Price Buy 50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: 33% - Buy 100-Day Average Volume - 17797
Overall Average: 72% - Buy
Price Support Pivot Point Resistance 1.1000 0.9600 1.0900 1.2200
IP: Logged |
posted
Last tuesday this was .75...Now up tp 1.75 .. Have been reading lots of good things about this environmentally friendly biothech. Word is getting out.... Low float could really make this pop with record volume.
IP: Logged |
Industrial Biotechnology Corporation's Chief Technologist Selected as Lead Speaker, Session Chair and Keynote Lecturer at AsianBio 2006 Tuesday October 31, 1:27 pm ET
SARASOTA, FL--(MARKET WIRE)--Oct 31, 2006 -- Industrial Biotechnology Corporation (Other OTC:IBTY.PK - News) (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, today announced that Gurinder Shahi, IBC's Chief Technologist and Scientific Advisory Board Chairman, has been selected to as a Lead Speaker, Session Chair and Keynote Lecturer at AsianBio 2006, the Third Asian Biotechnology Conference. ADVERTISEMENT
During the 2-day conference taking place in Manila on November 9-10, Dr. Shahi will be the lead speaker "Enabling Policy" and provide the keynote lecture on "Potentials & Constraints in Biomedical Biotechnology in Developing Countries." In addition to role at IBC, Dr. Shahi is also Chairman of BioEnterprise Asia and Director of the BioBusiness Initiative.
About AsianBio 2006 and the Third Asian Biotechnology Conference
The Third Asian Biotechnology Conference is intended to be a venue where major stakeholders, such as the government, academia, media as well as the international community, can converge, discuss issues, and establish linkages. It is envisioned to provide a forum for said stakeholders and other interest groups to formulate strategies that would enable developing countries to use biotechnology as an engine for growth and economic development.
Industrial Biotechnology Corporation (IBC) enables the biological production of chemicals through a combination of licensed patents, intellectual property and proprietary systems. We accomplish this through our ALCHEMx Productions Platforms(TM) which are a systematic, streamlined approach to biologically manufacture chemicals more efficiently, at significantly lower costs, and with substantially lower environmental impact than traditional methods. IBC and its partners plan to produce and market new and established biologically produced chemicals to the pharmaceutical, bio-energy, agricultural, biopesticides, fine chemicals, flavors and fragrances, cosmeceuticals, biomaterials and biopolymer industries. For more information about Industrial Biotechnology Corporation, please visit its website at
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
